|
American Academy of Pediatrics Council on Injury, Violence and Poison Prevention (AAP-COIVPP)
|
Committee, Work group, Advisory group, or Task Force
|
ACF, HRSA, IHS
|
NICHD
|
The AAP Council on Injury, Violence, and Poison Prevention addresses all facets of injury prevention policy, programs, advocacy, and education of general pediatricians, pediatric subspecialists, and families as a unified group.
|
|
American Community Survey (ACS) Interagency Committee Meeting
|
Meeting/ Workshop
|
ACF, AHRQ, ASPE, CDC, CMS, HRSA
|
NICHD
|
Coordinated by the U.S. Census Bureau
|
|
American Congress of Obstetricians and Gynecologists (ACOG) Committee on Gynecologic Practice
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NICHD
|
The National Institutes of Health (NIH) advises the American Congress of Obstetricians and Gynecologists (ACOG) Committee on Gynecologic Practice about research advances that can inform gynecologic clinical practice.
|
|
Americas Children Forum on Health and Family Statistics
|
Resource Development
|
SAMHSA
|
NIDA
|
As a member of this collaboration, the National Institute on Drug Abuse (NIDA) contributes data from the, “Monitoring the Future Survey on Illicit Drugs, Alcohol and Tobacco Trends”.
|
|
AMP Bespoke Gene Therapy Program/Bespoke Gene Therapy Consortium (BGTC)
|
Research Initiative
|
FDA
|
NHLBI, NCATS, NIMH, NINDS
|
The Bespoke Gene Therapy Consortium (BGTC) is a developing public-private partnership dedicated to making gene therapy a reality for people with rare genetic diseases affecting populations too small to be viable from the current commercial perspective.
|
|
Analgesic Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION)
|
Research Initiative
|
FDA
|
NINDS, NCATS, NCI, NIAAA, NIDA
|
The mission of the Analgesic Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership funded by the US Food and Drug Administration (FDA) is to identify, prioritize, sponsor, coordinate, and promote innovative activities — with a special interest in optimizing clinical trials — that will expedite the discovery and development of improved analgesic treatments for the benefit of the public health.
|
|
Analytical Methods and Reference Materials Program (AMRM)
|
Resource Development
|
FDA
|
OD/DPCPSI/ODS, NCCIH, NCI, NIDDK
|
The National Institutes of Health's, Office of Dietary Supplement Analytical Methods and Reference Materials Program (AMRM) collaborates with NIH ICOs and other federal agencies to support the development and dissemination of research resources that scientists and analysts need to ensure that chemical characterizations of dietary supplements, natural products, and nutrient biomarkers are accurate, precise, reliable, and reproducible.
|
|
Ancillary Swab Study to PREVENT-19 trial: Swab your Nose Inside to Find inFection (SNIFF)
|
Research Initiative
|
ASPR, CDC, FDA
|
NIAID
|
In this ancillary swab study, up to 3,000 adolescent participants 12-17 years of age who participated in the Pre-fusion Protein Subunit Vaccine Efficacy Novavax Trial COVID-19 (PREVENT-19) Pediatric Expansion study and who provided informed consent/assent for the ancillary swab study were sampled twice weekly starting at the day 21 visit, or as soon as possible thereafter, of the initial injection period until the second dose of the blinded cross-over (approximately 28 weeks) with nasal swabs for detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection by reverse transcription polymerase chain reaction (RT-PCR) and incident infections tallied. Data sources from the Observational Study (e.g., study product assignment, daily symptomatology) will be used in the ancillary study to estimate the vaccine efficacy against SARS-CoV-2 infection, including asymptomatic infection or mildly symptomatic infection not meeting the Coronavirus Disease 2019 (COVID-19) primary endpoint definition for the Phase 3 study.
|
|
Annual Conference on the Science of Dissemination and Implementation
|
Meeting/ Workshop
|
AHRQ, CDC
|
NCI, FIC, NHGRI, NHLBI, NIAAA, NIDA, NIDDK, NIMH, NIMHD, NINR, NIEHS, OD
|
Annual Conference on the Science of Dissemination and Implementation is a forum for discussing the science of dissemination and implementation and aims to grow the research base by bridging the gap between evidence, practice, and policy in health and medicine. Researchers, evaluators, and implementers who are interested in identifying opportunities, challenges, and strategies for disseminating the findings and implementation of research to key stakeholders are encouraged to attend. Discuss, debate, and explore in-depth approaches to advance dissemination and implementation science.
|
|
Antibody Interest Group (ABIG)
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NCI, NHLBI, NIAID, NIDCR, NIDDK
|
The NIH Antibody Interest Group (ABIG) promotes information exchange and interaction among NIH scientists who work on various aspects of antibody engineering and therapy. The success of antibody therapy requires a thorough understanding of biological systems in relation to molecular and cell biology, immunology, biochemistry, and microbiology, as well as diseases such as cancer, autoimmunity, and infectious diseases. Interest in antibody therapy crosses traditional biomedical disciplinary boundaries. ABIG provides an open forum for multidisciplinary discussion among colleagues who otherwise may have limited interaction. The principal ABIG activities are monthly meetings on current topics as well as an annual symposium on the NIH campus. The monthly ABIG meetings are open to everyone interested. These meetings are devoted to research seminars on numerous aspects of antibody engineering and therapy presented by both NIH scientists and outside speakers.
|